Downsized Miniature Swine: A New Spin On The Oldest Model

Nonclinical studies for advancing novel therapeutics into clinical trials often require the use of non-rodent laboratory species, with the choice typically based on metabolism for small molecules or pharmacology for biologics. Traditionally, nonhuman primates (NHPs) and beagle dogs have been the primary species used. However, growing pressure to limit the use of these animals in safety studies has created an opportunity to explore alternative models, such as miniature swine. Miniature swine share many metabolic similarities with humans, making them a viable option for small molecule studies. Additionally, as biologics continue to expand, miniature swine are increasingly recognized as a valuable alternative in cases where the pharmacological target is conserved across species.

Sinclair BioResources has further enhanced this model by developing the Sinclair Nanopig™, a downsized lineage of miniature swine comparable in size to a beagle dog, reaching sexual maturity by 4.5 months. This innovative model offers a powerful non-rodent alternative for nonclinical safety studies, with the added benefit of rapid reproduction to meet demand. Miniature swine models, including the Sinclair Nanopig™, are regularly used for nonclinical studies involving diverse routes of exposure and are now a highly attractive option in the current supply landscape.

This presentation, led by Dr. Scott Boley of Altasciences and Dr. Guy Bouchard and Dr. Derek Brocksmith of Sinclair BioResources, will explore the Sinclair Nanopig™ as a viable alternative to beagles and NHPs, highlighting its benefits for nonclinical programs. It is designed for nonclinical and clinical scientists, project directors, and senior biotech executives seeking innovative solutions for their research needs.